LadRx Corp Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>LadRx Corp filed its quarterly report (10-Q) for the period ending March 31, 2024, detailing its financial status and corporate information.</b>

AI Summary

LadRx Corp (LADX) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. LadRx Corp filed a 10-Q report for the period ending March 31, 2024. The company was formerly known as Cytrx Corp, with a name change on July 3, 1992. LadRx Corp is incorporated in Delaware and operates in the Biological Products sector. The filing includes data related to common stock, preferred stock, options, and warrants. Key dates mentioned include the filing date of May 15, 2024, and the period of report as March 31, 2024.

Why It Matters

For investors and stakeholders tracking LadRx Corp, this filing contains several important signals. This filing provides investors with an update on LadRx Corp's financial performance and position as of the first quarter of 2024. Understanding the details within this 10-Q is crucial for assessing the company's current operational health and future prospects.

Risk Assessment

Risk Level: low — LadRx Corp shows low risk based on this filing. The filing is a standard 10-Q, providing routine financial disclosures without immediate indicators of significant new risks or opportunities.

Analyst Insight

Review the detailed financial statements and any management discussion and analysis within the full 10-Q to understand the company's performance drivers and outlook.

Key Numbers

• 2024-03-31 — Period End Date (Reporting period for the 10-Q)
• 2024-05-15 — Filing Date (Date the 10-Q was filed)
• 0000799698 — Central Index Key (Company's unique identifier)
• 2836 — SIC Code (Standard Industrial Classification for Biological Products)

Key Players & Entities

• LadRx Corp (company) — Filer and company name
• LADX (company) — Ticker symbol
• Cytrx Corp (company) — Former company name
• DE (company) — State of incorporation
• 2024-05-15 (date) — Filing date
• 2024-03-31 (date) — Period of report
• 1934 Act (regulator) — SEC Act
• 000-15327 (regulator) — SEC File Number

FAQ

Key Dates

• 2024-05-15: 10-Q Filing — Report filed for the period ending March 31, 2024
• 2024-03-31: Period of Report End Date — Marks the end of the financial reporting quarter
• 1992-07-03: Name Change — Date LadRx Corp changed its name from Cytrx Corp

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC). (Provides an update on the company's financial performance and position during the quarter.)

Central Index Key (CIK)

A unique identifier assigned to each entity that files with the SEC. (Helps in tracking filings and identifying specific companies within SEC databases.)

Standard Industrial Classification (SIC)

A system used to classify industries and businesses. (Indicates the primary business activity of the company, in this case, Biological Products.)

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share LADX OTC Market
• $1 million — ed to receive (i) a one-time payment of $1 million upon acceptance of a re-submission of a

Filing Documents

• form10-q.htm (10-Q) — 489KB
• ex31-1.htm (EX-31.1) — 8KB
• ex31-2.htm (EX-31.2) — 8KB
• ex32-1.htm (EX-32.1) — 5KB
• ex32-2.htm (EX-32.2) — 5KB
• 0001493152-24-019407.txt (&nbsp;) — 2844KB
• ladx-20240331.xsd (EX-101.SCH) — 22KB
• ladx-20240331_cal.xml (EX-101.CAL) — 27KB
• ladx-20240331_def.xml (EX-101.DEF) — 122KB
• ladx-20240331_lab.xml (EX-101.LAB) — 210KB
• ladx-20240331_pre.xml (EX-101.PRE) — 162KB
• form10-q_htm.xml (XML) — 336KB

— FINANCIAL INFORMATION

PART I. — FINANCIAL INFORMATION 4 Item 1. Condensed Financial Statements (unaudited) 4 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 20 Item 4.

Controls and Procedures

Controls and Procedures 20

— OTHER INFORMATION

PART II. — OTHER INFORMATION 21 Item 1.

Legal Proceedings

Legal Proceedings 21 Item 1A

Risk Factors

Risk Factors 21 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 21 Item 3. Defaults Upon Senior Securities 21 Item 4. Mine Safety Disclosure 21 Item 5. Other Information 21 Item 6. Exhibits 21

SIGNATURES

SIGNATURES 22 INDEX TO EXHIBITS 23 2 Forward Looking Statements All than statements of historical fact are forward-looking statements, including statements of our current views with respect to the recent developments regarding our business strategy, business plan and research and development activities, our future financial results, and other future events. These statements include forward-looking statements both with respect to us, specifically, and the biotechnology industry, in general. In some cases, forward-looking statements can be identified by the use of terminology such as "may," "will," "expects," "plans," "anticipates," "estimates," "potential" or "could" or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, there can be no assurance that such expectations or any of the forward-looking All forward-looking statements involve inherent risks and uncertainties, and there are or will be important factors that could cause actual results to differ materially from those indicated in these statements. We believe that these factors include, but are not limited to, the factors discussed in this section and under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Annual Report"), which should be reviewed carefully. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we anticipate. Please consider our forward-looking statements in light of those risks as you read this Quarterly Report. We undertake no

View Full Filing

View this 10-Q filing on SEC EDGAR